Table 1:
Baseline demographics of eyes with and without extramacular drusen
| Total | Absent* | Present | |
|---|---|---|---|
| N (Col%) | N (Col%) | N (Col%) | |
| Total | 4168 (100%) | 544 (100%) | 3624 (100%) |
| Age (mean SD) | 72.4 (8.0) | 72.7(8) | 72.3(8) |
| Sex | |||
| Female | 2540 (60.9%) | 298 (54.8%) | 2242 (61.9%) |
| Male | 1628 (39.1%) | 246 (45.2%) | 1382 (38.1%) |
| Smoking | |||
| Never | 1948 (46.7%) | 221 (40.6%) | 1727 (47.7%) |
| Former | 1976 (47.4%) | 291 (53.5%) | 1685 (46.4%) |
| Current | 244 (5.9%) | 32 (5.9%) | 212 (5.8%) |
| History of diabetes | |||
| No | 3694 (88.6%) | 456 (83.8%) | 3238 (89.3%) |
| Yes | 474 (11.4%) | 88 (16.2%) | 386 (10.7%) |
| History of hypertension | |||
| Unknown | 11 (0.3%) | 0 (0%) | 11 (0.3%) |
| No | 1847 (44.3%) | 220 (40.4%) | 1627 (44.9%) |
| Yes | 2310 (55.4%) | 324 (59.6%) | 1986 (54.8%) |
| History of angina | |||
| Unknown | 20 (0.5%) | 3 (0.6%) | 17 (0.5%) |
| No | 3976 (95.4%) | 510 (93.8%) | 3466 (95.6%) |
| Yes | 172 (4.1%) | 31 (5.7%) | 141 (3.9%) |
| Statin use | |||
| No | 2431 (58.3%) | 297 (54.6%) | 2134 (58.9%) |
| Yes | 1737 (41.7%) | 247 (45.4%) | 1490 (41.1%) |
| AREDS2 treatment | |||
| Control | 1010 (24.2%) | 124 (22.8%) | 886 (24.4%) |
| Lutein/Zeaxanthin | 1028 (24.7%) | 126 (23.2%) | 902 (24.9%) |
| DHA/EPA | 1065 (25.6%) | 144 (26.5%) | 921 (25.4%) |
| Combo | 1065 (25.6%) | 150 (27.6%) | 915 (25.2%) |
| Baseline Visual Acuity | |||
| <20/200 | 32 (0.8%) | 4(0.7%) | 28(0.8%) |
| <20/40–20/200 | 394 (9.5%) | 59(10.8%) | 335(9.2%) |
| <20/20–20/40 | 2104 (50.5%) | 306(56.3%) | 1798(49.6%) |
| 20/20+ | 1630 (39.1%) | 174(32.0%) | 1456(40.2%) |
| Missing | 8(0.2%) | 1(0.2%) | 7(0.2%) |
No significant different in all variables between eyes with and without EMD (p > 0.05)
*
Absent includes eyes with no drusen and with reticular pseudodrusen only and cuticular drusen only. AREDS2 = Age-related Eye Disease Study 2; DHA/EPA= docosahexaenoic acid /eicosapentaenoic acid